Jun 17, 2010 - 11:20 am
I read this new report from the prostate cancer info link, doesn't surprise me, and believe me it is the worst possible disease, it's an autoimmune disease where the body attacks the penis. This report says the risk after RP increases by double or three fold.
Peyronie’s disease (PD) is a clinical condition characterized by an upward curvature of the erect penis. It is known to occur with regularity in men between about 45 and 75 years of age. A thorough overview of this condition by Lizza can be found on the eMedicine web site.
What we really don’t know so much about includes:
The true incidence and prevalence of PD
Historically, PD was not something most men rushed to their doctors to talk about. It’s symptoms may be mild and have little impact on men’s lives. It may be preceded by erectile dysfunction. It is also commonly preceded by and associated with painful erections. But it is an embarrassing condition for most men, and so if they have never been to their doctor for another urological condition, they may only mention this when it becomes a significant problem.
Thus, from an epidemiological point of view, all we really know is that the reported rate of PD in men as a whole is around 0.5 to 3 percent, although Mulhall et al. reported a prevalence of 8.9 percent in a series of men being screened for prostate cancer.
Tal et al. have now published detailed data on the incidence of PD in in a series of > 1,000 patients after radical prostatectomy for prostate cancer and have made an initial attempt to determine possible predictors of the occurrence of after an RP.
Between 2000 and 2008, researchers at Memorial Sloan-Kettering Cancer Center developed a sexual medicine database, focused primarily on men who were treated with an RP as their primary therapy for localized prostate cancer. Tal et al. then used this database to identify patients who developed PD within 3 years of their RP and compared them with the patients who did not.
The results of this study show the following:
The total study population included 1,011 men who had received and RP as their only treatment for localized prostate cancer.
White race showed a much higher risk (HR = 4.1) for PD after RP than non-white.
However, it is notable that the authors still do not conclude from this study that RP is a specific cause of PD. Indeed, they state specifically that additional studies will be needed “to conclude if RP has a causative role in the pathogenesis of PD.”
There seems to be little doubt that RP is at least a potential and significant risk factor for PD in some groups of men, and the authors recommend that RP patients should be monitored post-surgery for PD. Having said that, it should be noted that effective treatments for PD are limited in their value, and most men with PD should be carefully monitored in the early stages of the disease as opposed to taking any immediate, radical steps to correct the condition.